ALBANY, N.Y. and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization and Carterra Inc., the world leader in label–free high throughput [...] Read more »
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors
Read more »
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) — Biolojic Design, a biotechnology company that uses AI to transform antibodies into intelligent medicinal solutions, today announced that Nektar [...] Read more »
Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award
WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician–researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star [...] Read more »
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) — The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most [...] Read more »
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, [...] Read more »
Fortrea signe un accord définitif pour céder les activités Endpoint Clinical et Patient Access à Arsenal Capital Partners
Le projet de cession des activités Endpoint Clinical et Fortrea Patient Access permet à Fortrea de se recentrer sur son cœur de métier stratégique d’organisme de [...] Read more »
Fortrea unterzeichnet endgültige Vereinbarung zur Veräußerung der Geschäftsbereiche Endpoint Clinical und Patient Access an Arsenal Capital Partners
Vorgeschlagene Veräußerung der Geschäftsbereiche Endpoint Clinical und Fortrea Patient Access optimiert Fortreas strategische Ausrichtung als reines Auftragsforschungsinstitut
Read more »
Fortrea Assina Contrato Definitivo de Transferência das Unidades Endpoint Clinical e Patient Access para a Arsenal Capital Partners
A proposta da transferência das unidades Endpoint Clinical e Fortrea Patient Access agiliza ainda mais o foco estratégico da Fortrea como uma organização de pesquisa sob contrato
Read more »
Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners
Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea’s strategic focus as a pure–play contract research organization
Read more »